<DOC>
	<DOCNO>NCT00400322</DOCNO>
	<brief_summary>The purpose study investigate treatment CMV infection antiviral drug Valcyte ( R ) affect clinical outcome glioblastoma multiforme patient local CMV infection tumor tissue . The investigator ' hypothesis state CMV infection promote tumor development disease progression inhibit immune response tumor .</brief_summary>
	<brief_title>Efficacy Safety ValcyteÂ® Add-on Therapy Patients With Malignant Glioblastoma Cytomegalovirus ( CMV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Glioblastoma grade IV Cytomegalovirus detect tumor At least 90 % resection tumor Decreased kidney function Pregnancy Neutropenia Thrombocytopenia Patient tolerate drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>cytomegalovirus infection</keyword>
	<keyword>antiviral treatment</keyword>
	<keyword>valganciclovir</keyword>
</DOC>